Details of the Drug

General Information of Drug (ID: DM9KZDO)

Drug Name
Esterified estrogens
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [1]
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 1 - 2 hours [2]
Metabolism
The drug is metabolized via the hepatic []
Cross-matching ID
UNII
3ASP8Q3768
DrugBank ID
DB09381
TTD ID
D0R6RE

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Esterified estrogens
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Tucatinib DMBESUA Moderate Decreased metabolism of Esterified estrogens caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [4]
Coadministration of a Drug Treating the Disease Different from Esterified estrogens (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Esterified estrogens caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [5]
Arn-509 DMT81LZ Moderate Increased metabolism of Esterified estrogens caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [5]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Esterified estrogens caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [5]
MK-8228 DMOB58Q Moderate Decreased metabolism of Esterified estrogens caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [6]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Esterified estrogens caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [5]
Tazemetostat DMWP1BH Moderate Increased metabolism of Esterified estrogens caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [7]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Esterified estrogens caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [8]
Brigatinib DM7W94S Moderate Increased metabolism of Esterified estrogens caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [9]
PF-06463922 DMKM7EW Moderate Increased metabolism of Esterified estrogens caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [5]
Selpercatinib DMZR15V Moderate Decreased metabolism of Esterified estrogens caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [10]
IPI-145 DMWA24P Moderate Decreased metabolism of Esterified estrogens caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [11]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Esterified estrogens caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [10]
Abametapir DM2RX0I Moderate Decreased metabolism of Esterified estrogens caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [12]
Lefamulin DME6G97 Moderate Decreased metabolism of Esterified estrogens caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [13]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Esterified estrogens caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [14]
Larotrectinib DM26CQR Moderate Decreased metabolism of Esterified estrogens caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [6]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Esterified estrogens caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [15]
⏷ Show the Full List of 17 DDI Information of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2011 Jan;95(1):366-8.
4 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
5 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
6 Cerner Multum, Inc. "Australian Product Information.".
7 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
8 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
9 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
10 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
11 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
12 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
13 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
14 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
15 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.